Aurinia Pharmaceuticals (AUPH) Stock Rating Upgraded by ValuEngine

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) was upgraded by stock analysts at ValuEngine from a “sell” rating to a “hold” rating in a report released on Sunday.

Several other research analysts have also recently commented on AUPH. Vetr cut shares of Aurinia Pharmaceuticals from a “buy” rating to a “hold” rating and set a $6.64 target price for the company. in a research report on Wednesday, September 6th. Seaport Global Securities restated a “buy” rating and issued a $10.00 target price on shares of Aurinia Pharmaceuticals in a research report on Friday, October 6th. Cantor Fitzgerald restated a “buy” rating and issued a $14.00 target price on shares of Aurinia Pharmaceuticals in a research report on Monday, October 23rd. Leerink Swann upped their target price on shares of Aurinia Pharmaceuticals from $10.00 to $14.00 and gave the stock an “outperform” rating in a research report on Monday, October 23rd. Finally, Zacks Investment Research cut shares of Aurinia Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, October 24th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $10.79.

Aurinia Pharmaceuticals (NASDAQ:AUPH) traded down $0.12 during midday trading on Friday, reaching $4.53. 1,373,800 shares of the company’s stock traded hands, compared to its average volume of 1,015,549. Aurinia Pharmaceuticals has a 1 year low of $2.09 and a 1 year high of $10.54. The company has a market cap of $380.40, a PE ratio of -3.43 and a beta of 2.35.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its earnings results on Tuesday, November 14th. The biotechnology company reported ($0.16) EPS for the quarter, missing the consensus estimate of ($0.14) by ($0.02). Aurinia Pharmaceuticals had a negative return on equity of 25.56% and a negative net margin of 18,089.02%. The firm had revenue of $0.03 million during the quarter, compared to the consensus estimate of $0.03 million. The business’s revenue for the quarter was up .0% on a year-over-year basis. analysts anticipate that Aurinia Pharmaceuticals will post -1.05 EPS for the current year.

Institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. boosted its holdings in shares of Aurinia Pharmaceuticals by 357.3% in the second quarter. Goldman Sachs Group Inc. now owns 876,461 shares of the biotechnology company’s stock valued at $5,373,000 after acquiring an additional 684,816 shares in the last quarter. FMR LLC boosted its holdings in shares of Aurinia Pharmaceuticals by 0.3% in the second quarter. FMR LLC now owns 5,867,800 shares of the biotechnology company’s stock valued at $35,969,000 after acquiring an additional 19,200 shares in the last quarter. AWM Investment Company Inc. boosted its holdings in shares of Aurinia Pharmaceuticals by 17.5% in the second quarter. AWM Investment Company Inc. now owns 352,500 shares of the biotechnology company’s stock valued at $2,161,000 after acquiring an additional 52,500 shares in the last quarter. Kazazian Asset Management LLC boosted its holdings in shares of Aurinia Pharmaceuticals by 47.3% in the second quarter. Kazazian Asset Management LLC now owns 66,304 shares of the biotechnology company’s stock valued at $406,000 after acquiring an additional 21,304 shares in the last quarter. Finally, Balyasny Asset Management LLC boosted its holdings in shares of Aurinia Pharmaceuticals by 66.7% in the second quarter. Balyasny Asset Management LLC now owns 500,000 shares of the biotechnology company’s stock valued at $3,065,000 after acquiring an additional 200,000 shares in the last quarter. Institutional investors and hedge funds own 28.13% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Aurinia Pharmaceuticals (AUPH) Stock Rating Upgraded by ValuEngine” was originally published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this article on another website, it was stolen and republished in violation of US & international trademark & copyright legislation. The legal version of this article can be viewed at https://www.chaffeybreeze.com/2017/12/31/aurinia-pharmaceuticals-auph-stock-rating-upgraded-by-valuengine.html.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Analyst Recommendations for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply